A5089237578- Glioma Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Meningioma and schwannoma management
- Vascular Malformations Diagnosis and Treatment
- Brain Metastases and Treatment
- Cancer, Hypoxia, and Metabolism
- Cancer Genomics and Diagnostics
- MicroRNA in disease regulation
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Immune cells in cancer
- Immune Cell Function and Interaction
- Neuroblastoma Research and Treatments
- Neuroinflammation and Neurodegeneration Mechanisms
- MRI in cancer diagnosis
- Ferroptosis and cancer prognosis
- Mitochondrial Function and Pathology
- Advanced Neuroimaging Techniques and Applications
- Single-cell and spatial transcriptomics
- Neurofibromatosis and Schwannoma Cases
- Advanced MRI Techniques and Applications
- Cerebrospinal fluid and hydrocephalus
- Histone Deacetylase Inhibitors Research
- Sarcoma Diagnosis and Treatment
- Spinal Hematomas and Complications
Kyushu University
2016-2025
Kyoto University
2016-2024
Neurological Surgery
2021-2024
University of California, San Francisco
2021-2024
Ureshino Medical Center
2014
National Hospital Organization
2012-2014
Abstract Small, soluble metabolites not only are essential intermediates in intracellular biochemical processes, but can also influence neighbouring cells when released into the extracellular milieu 1–3 . Here we identify metabolite and neurotransmitter GABA as a candidate signalling molecule synthesized secreted by activated B plasma cells. We show that cell-derived promotes monocyte differentiation anti-inflammatory macrophages secrete interleukin-10 inhibit CD8 + T cell killer function....
The prognostic impact of TERT mutations has been controversial in IDH-wild tumors, particularly glioblastomas (GBM). controversy may be attributable to presence potential confounding factors such as MGMT methylation status or patients' treatment. This study aimed evaluate the on patient outcome association with various a large series adult diffuse gliomas. We analyzed total 951 gliomas from two cohorts (Cohort 1, n = 758; Cohort 2, 193) for IDH1/2, 1p/19q, and promoter status. combined...
<h3>BACKGROUND AND PURPOSE:</h3> Glioblastoma multiforme is highly aggressive and the most common type of primary malignant brain tumor in adults. Imaging biomarkers may provide prognostic information for patients with this condition. Patients glioma <i>isocitrate dehydrogenase 1</i> (<i>IDH1</i>) mutations have a better clinical outcome than those without such mutations. Our purpose was to investigate whether <i>IDH1</i> mutation status glioblastoma can be predicted by using MR imaging....
Many conventional chemotherapeutic drugs exert their cytotoxic function by inducing DNA damage in the tumor cell. Therefore, a cell-inherent repair pathway, which reverses DNA-damaging effect of drugs, can mediate therapeutic resistance to chemotherapy. The monofunctional DNA-alkylating agent temozolomide (TMZ) is commonly used drug and gold standard treatment for glioblastoma. Although activity protein O6-methylguanine-DNA methyltransferase (MGMT) has been described as main modulator...
BACKGROUNDPrecise stratification of patients with non-small cell lung cancer (NSCLC) is needed for appropriate application PD-1/PD-L1 blockade therapy.METHODSWe measured soluble forms the immune-checkpoint molecules PD-L1, PD-1, and CTLA-4 in plasma advanced NSCLC before blockade. A prospective biomarker-finding trial (cohort A) included 50 previously treated who received nivolumab. retrospective observational study was performed any therapy (cohorts B C), cytotoxic chemotherapy D), or...
The efficacy of chimeric antigen receptor T cell (CAR-T) therapy has been limited against brain tumors to date. CAR-T cells infiltrating syngeneic intracerebral SB28 EGFRvIII gliomas revealed impaired mitochondrial ATP production and a markedly hypoxic status compared with ones migrating subcutaneous tumors. Drug screenings improve metabolic states under conditions led us evaluate the combination AMPK activator metformin mTOR inhibitor rapamycin (Met+Rap). Met+Rap-pretreated mouse showed...
BACKGROUNDCurrent clinical biomarkers for the programmed cell death 1 (PD-1) blockade therapy are insufficient because they rely only on tumor properties, such as ligand expression frequency and mutation burden. Identifying reliable, responsive based host immunity is necessary to improve predictive values.METHODSWe investigated levels of plasma metabolites T including energy metabolism markers, in blood patients with non-small lung cancer before after treatment nivolumab (n = 55). Predictive...
Conventional genetic analyzers require surgically obtained tumor tissues to confirm the molecular diagnosis of diffuse glioma. Recent technical breakthroughs have enabled increased utilization cell-free DNA (ctDNA) in body fluids as a reliable resource for various cancers. Here, we tested application chip-based digital PCR system less invasive (i.e., liquid biopsy) glioma using cerebrospinal fluid (CSF).CSF samples from 34 patients with were collected surgical field during craniotomy....
High resolution melting (HRM) is a simple and rapid method for screening mutations. It offers various advantages clinical diagnostic applications. Conventional HRM analysis often yields equivocal results, especially surgically obtained tissues. We attempted to improve analyses more effective applications diagnostics. were performed IDH1R132 IDH2R172 mutations in 192 glioma samples duplicate these results compared with sequencing results. BRAFV600E analyzed 52 additional brain tumor samples....
Abstract TERT promoter mutations are commonly associated with 1p/19q codeletion in IDH-mutated gliomas. However, whether these have an impact on patient survival independent of is unknown. In this study, we investigated the glioma cases. Detailed clinical information and molecular status data were collected for a cohort 560 adult patients Among patients, 279 had both mutation codeletion, while 30 either (n = 24) or 6) alone. A univariable Cox proportional hazard analysis using genetic...
Current clinically approved biomarkers for the PD-1 blockade cancer immunotherapy are based entirely on properties of tumour cells. With increasing awareness clinical responses, more precise efficacy required immune properties. In particular, expression levels checkpoint-associated molecules such as PD-1, PD-L1, and CTLA-4 would be critical to evaluate state individuals. Although quantification their soluble form leased from membrane will provide quick evaluation patients' status, available...
Abstract Objective Accumulating evidence from recent molecular diagnostic studies has indicated the prognostic significance of various genetic markers for patients with glioblastoma (GBM). To evaluate impact such on prognosis, we retrospectively analyzed outcomes IDH ‐wildtype GBM in our institution. In addition, to assess bevacizumab (BEV) treatment, compared overall survival (OS) between pre‐ and post‐BEV eras. Methods We data 100 adult (over 18 years old) database February 2006 October...
Brain tumors harbor various BRAF alterations, the vast majority of which are kinase‐activating V600E mutation. mutations most frequently detected in certain subtypes low‐grade glioma, such as pilocytic astrocytoma (PA), pleomorphic xanthoastrocytoma (PXA), ganglioglioma (GG) and dysembryoplastic neuroepithelial tumor (DNT). However, it is unclear whether gliomas harboring can be invariably regarded these glioma or their derivatives. To address this question, we analyzed 274 our institutional...
Targeting the unique glioma immune microenvironment is a promising approach in developing breakthrough immunotherapy treatments. However, recent advances immunotherapy, including development of checkpoint inhibitors, have not improved outcomes patients with glioma. A way monitoring biological activity cells neural tissues affected by should be developed to address this lack sensitivity immunotherapy. Thus, study, we sought examine feasibility non-invasive glioma-associated...
Despite the success of cancer immunotherapies such as programmed cell death-1 (PD-1) and PD-1 ligand 1 (PD-L1) inhibitors, patients often develop resistance. New combination therapies with PD-1/PD-L1 inhibitors are needed to overcome this issue. Bezafibrate, a peroxisome proliferator-activated receptor-γ coactivator 1α/peroxisome receptor complexes, has shown synergistic antitumor effect blockade in mice that is mediated by activation mitochondria T cells. We have therefore now performed...
Abstract High vascularization is a biological characteristic of glioblastoma (GBM); however, an in-vitro experimental model to verify the mechanism and physiological role vasculogenesis in GBM not well-established. Recently, we established self-organizing vasculogenic using human umbilical vein endothelial cells (HUVECs) co-cultivated with lung fibroblasts (hLFs). Here, exploited this system establish realistic GBM. We developed two polydimethylsiloxane (PDMS) devices, doughnut-hole dish...
Craniopharyngioma consists of adamantinomatous and papillary subtypes. Recent genetic analysis has demonstrated that the two subtypes are different, not only in clinicopathological features, but also molecular oncogenesis. Papillary craniopharyngioma (pCP) is characterized by a BRAF mutation, V600E (Val 600 Glu) mutation. Adamantinomatous (aCP) can be distinguished frequent β-catenin gene (CTNNB1) mutations. Although these alterations diagnostic marker, precise frequency mutations clinical...